Golden Biotechnology (Taiwan) Performance
| 4132 Stock | TWD 15.10 0.05 0.33% |
The company retains a Market Volatility (i.e., Beta) of 0.57, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Golden Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Golden Biotechnology is expected to be smaller as well. At this point, Golden Biotechnology has a negative expected return of -0.0139%. Please make sure to check out Golden Biotechnology's jensen alpha, treynor ratio, and the relationship between the standard deviation and total risk alpha , to decide if Golden Biotechnology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Golden Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Golden Biotechnology is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Quick Ratio | 0.92 | |
| Fifty Two Week Low | 26.31 | |
| Fifty Two Week High | 64.99 |
Golden |
Golden Biotechnology Relative Risk vs. Return Landscape
If you would invest 1,560 in Golden Biotechnology on December 25, 2024 and sell it today you would lose (50.00) from holding Golden Biotechnology or give up 3.21% of portfolio value over 90 days. Golden Biotechnology is generating negative expected returns and assumes 3.1049% volatility on return distribution over the 90 days horizon. Simply put, 27% of stocks are less volatile than Golden, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Golden Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Golden Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Golden Biotechnology, and traders can use it to determine the average amount a Golden Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0045
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 4132 |
Estimated Market Risk
| 3.1 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Golden Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Golden Biotechnology by adding Golden Biotechnology to a well-diversified portfolio.
Golden Biotechnology Fundamentals Growth
Golden Stock prices reflect investors' perceptions of the future prospects and financial health of Golden Biotechnology, and Golden Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Golden Stock performance.
| Return On Equity | -36.95 | |||
| Return On Asset | -17.85 | |||
| Operating Margin | (414.69) % | |||
| Current Valuation | 5.17 B | |||
| Shares Outstanding | 115.76 M | |||
| Price To Book | 6.75 X | |||
| Price To Sales | 65.71 X | |||
| Revenue | 78.35 M | |||
| EBITDA | (279.28 M) | |||
| Cash And Equivalents | 152.56 M | |||
| Cash Per Share | 1.33 X | |||
| Total Debt | 227.3 M | |||
| Debt To Equity | 30.10 % | |||
| Book Value Per Share | 6.59 X | |||
| Cash Flow From Operations | (306.43 M) | |||
| Earnings Per Share | (2.97) X | |||
About Golden Biotechnology Performance
Evaluating Golden Biotechnology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Golden Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Golden Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Golden Biotechnology Corporation operates as a drug discovery and healthy food supplement manufacturing company. Golden Biotechnology Corporation was founded in 2002 and is based in New Taipei City, Taiwan. GOLDEN BIOTECHNOLOGY operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 135 people.Things to note about Golden Biotechnology performance evaluation
Checking the ongoing alerts about Golden Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Golden Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Golden Biotechnology generated a negative expected return over the last 90 days | |
| Golden Biotechnology has high historical volatility and very poor performance | |
| The company reported the revenue of 78.35 M. Net Loss for the year was (336.49 M) with profit before overhead, payroll, taxes, and interest of 51.31 M. | |
| Golden Biotechnology has accumulated about 152.56 M in cash with (306.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.33. |
- Analyzing Golden Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Golden Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Golden Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Golden Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Golden Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Golden Biotechnology's stock. These opinions can provide insight into Golden Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Golden Stock Analysis
When running Golden Biotechnology's price analysis, check to measure Golden Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Golden Biotechnology is operating at the current time. Most of Golden Biotechnology's value examination focuses on studying past and present price action to predict the probability of Golden Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Golden Biotechnology's price. Additionally, you may evaluate how the addition of Golden Biotechnology to your portfolios can decrease your overall portfolio volatility.